Bank of America is funding weight-loss medication for employees at a cost of at least $250 million per year, according to statements from CEO Brian Moynihan. The program covers GLP-1 drugs, which are used for weight management and related health benefits. Moynihan says GLP-1 medications now make up about 13% of the bank’s total annual healthcare spending, indicating the drugs have become a significant component of its benefits costs.
Both outlets report that the bank acknowledges employees may not stay long enough to realize long-term benefits from the treatment. Moynihan’s comments reflect awareness that some participants could leave the company before experiencing the full health outcomes intended by the program.
The reporting does not provide additional details in these articles about eligibility rules, specific medication types beyond GLP-1s, expected effects on employee health, or how the company measures results. The figures cited focus on annual spending and the share of overall healthcare costs attributable to GLP-1 drugs.
